Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Kelly-Anne Phillips, Julie Aldridge, Karin Ribi, Zhuoxin Sun, Alastair Thompson, Vernon Harvey, Beat Thuerlimann, Fatima Cardoso, Olivia Pagani, Alan S Coates, Aron Goldhirsch, Karen N Price, Richard D Gelber, Juerg Bernhard
Breast Cancer Research and Treatment | SPRINGER | Published : 2011
Awarded by National Cancer Institute at the National Institutes of Health
Awarded by NATIONAL CANCER INSTITUTE
We thank the patients who participated in this trial, collaborators, and funding sources. Acknowledgment for respective individuals involved in the various groups is given in the Appendix. This work was supported by Novartis and coordinated by IBCSG. Support for the IBCSG: Swedish Cancer Society; The Cancer Council Australia; Australian New Zealand Breast Cancer Trials Group; Frontier Science and Technology Research Foundation; Swiss Group for Clinical Cancer Research (SAKK); National Cancer Institute at the National Institutes of Health (Grant number CA-75362); Cancer Research Switzerland/Oncosuisse; and the Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK); The Cancer Council Victoria, Dr. John Colebatch Clinical Research Fellowship (to K. A. P).